

## Summary of status of development and availability of A(H7) candidate vaccine viruses and potency testing reagents\*

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise indicated all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test.

[National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)

**27 February 2026**

### Candidate vaccine viruses\*

Subtype	Antigenic prototype	Clade	Candidate vaccine virus	Type of virus or reassortant	Developing Institute	Available from
H7N1	A/mallard/Netherlands/12/2000	Eurasian	NIBRG-63 <sup>#*</sup>	Wild type virus	MHRA, UK	WHO CCs
	A/turkey/Italy/3889/99	Eurasian		Reverse genetics		MHRA, UK
H7N2	A/New York/107/2003	American	NIBRG-109 <sup>*</sup>	Wild type virus	MHRA, UK	WHO CCs
	A/turkey/Virginia/4529/2002	American		Reverse genetics		MHRA, UK
H7N3	A/Canada/rv444/2004	American	161984-B <sup>*</sup>	Wild type virus	SICRH, USA	WHO CCs
				Reverse genetics		CDC, USA
	A/mallard/Netherlands/12/2000	Eurasian	Wild type virus	MHRA, UK	MHRA, UK	
H7N7	A/mallard/Netherlands/12/2000	Eurasian	IBCDC-1 <sup>¥*</sup>	Wild type viruses	CDC, USA	WHO CCs
				Classical reassortant		CDC, USA

<sup>#</sup> HA from A/mallard/Netherlands/12/2000 and NA from A/Puerto Rico/8/34.

<sup>¥</sup> HA from A/mallard/Netherlands/12/2000 and NA from A/mallard/Netherlands/2/2000.

\*These viruses are candidate vaccine viruses which have passed relevant safety testing. They can be handled under BSL-2 enhanced containment<sup>1</sup>.

<sup>1</sup> [Guidelines for the safe development and production of vaccines to human pandemic influenza viruses and influenza viruses with pandemic potential, Annex 3, TRS No 1016 \(who.int\)](#)

## Candidate vaccine viruses in preparation

Subtype	Antigenic prototype	Clade	Developing Institute	Available from
H7N4	A/chicken/Jiangsu/1/2018-like	Eurasian	CCDC, China	Pending

### Institutes contact details for candidate vaccine virus orders and other information:

CCDC: [fluchina@ivdc.chinacdc.cn](mailto:fluchina@ivdc.chinacdc.cn)

CDC: [cvvrequest@cdc.gov](mailto:cvvrequest@cdc.gov) (Subject: CVV request)

MHRA: [standards@mhra.gov.uk](mailto:standards@mhra.gov.uk) or [enquiries@mhra.gov.uk](mailto:enquiries@mhra.gov.uk)

SJCRH: [richard.webby@stjude.org](mailto:richard.webby@stjude.org)

WHO CCs: <https://www.who.int/initiatives/global-influenza-surveillance-and-response-system/who-collaboration-center-erl?CxitPEOtTWx0xUd5TJdODSXcnyJqzYd7FZeivpn7xcl=>

**Reference antigens (freeze-dried)**

Parent virus	Starting materials		Ref Ag / Lot number	Unitage (µgHA/mL)	Available from
	CVV	Egg or Cell			
A/mallard/Netherlands/12/2000	NIBRG-60	Egg	07/336	115	MHRA, UK
A/New York/107/2003	NIBRG-109	Egg	08/362	To be announced	

**Sheep antisera**

Purified HA from		Order Lot number	Available from
Parent virus	Egg or Cell		
A/mallard/Netherlands/12/2000	Egg	07/278	MHRA, UK
A/New York/107/2003	Egg	09/148	
A/chick/Italy/1374/99 (H7N1)	Egg	02/294	

**WHO Essential Regulatory Laboratories (ERLs) contact details for reagent orders and other information:**

**MHRA:** [standards@mhra.gov.uk](mailto:standards@mhra.gov.uk) or [enquiries@mhra.gov.uk](mailto:enquiries@mhra.gov.uk)

For information of other type and subtype candidate vaccine viruses and potency testing reagents, please go to: (<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/zoonotic-influenza-viruses-and-candidate-vaccine-viruses>).

For general enquiries, please contact [gisrs-whohq@who.int](mailto:gisrs-whohq@who.int)